Stocks and InvestingStocks and Investing
Wed, September 2, 2015
Tue, September 1, 2015
Mon, August 31, 2015
Sat, August 29, 2015
Fri, August 28, 2015
Thu, August 27, 2015
Wed, August 26, 2015
Tue, August 25, 2015
Mon, August 24, 2015
Fri, August 21, 2015
Thu, August 20, 2015
Wed, August 19, 2015
Tue, August 18, 2015
Mon, August 17, 2015
Fri, August 14, 2015
Thu, August 13, 2015
Wed, August 12, 2015
Tue, August 11, 2015
Mon, August 10, 2015
Fri, August 7, 2015
Thu, August 6, 2015
Wed, August 5, 2015

Andrew Peters Maintained (BMRN) at Strong Buy with Increased Target to $160 on, Aug 5th, 2015


Published on 2024-10-25 09:38:25 -
  Print publication without navigation


Andrew Peters of Deutsche Bank, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Increased Target from $156 to $160 on, Aug 5th, 2015.

Andrew has made no other calls on BMRN in the last 4 months.



There are 5 other peers that have a rating on BMRN. Out of the 5 peers that are also analyzing BMRN, 0 agree with Andrew's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Andrew


  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $168 on, Tuesday, August 4th, 2015
  • Cory Kasimov of "JP Morgan" Maintained at Buy with Increased Target to $151 on, Thursday, June 18th, 2015
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $156 on, Thursday, June 18th, 2015
  • Kennen MacKay of "RBC Capital" Maintained at Buy with Increased Target to $145 on, Thursday, June 18th, 2015
  • Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $150 on, Thursday, June 18th, 2015